COST OF TARGETED
THERAPY WORLDWIDE
The list price is not what most insured patients pay. The actual cost conversation requires knowing your specific coverage, assistance programme eligibility, and access pathways -- and it belongs at the beginning.
analyticsAt a Glance
- check_circleTargeted therapies in the US typically cost $100,000β$300,000 per year
- check_circleIndia, China, and South Korea offer licensed generics and biosimilars at 60β80% lower cost
- check_circleSome countries offer patient assistance programmes or public insurance coverage
- check_circleCancerFax helps patients compare treatment costs and access affordable targeted therapy globally
Cost and Access by Healthcare System
| System / Country | Patient Cost | Notes |
|---|---|---|
| UK (NHS) | Typically no cost for NICE-approved drugs | Coverage determined by approved indication; limited centres for some specialist drugs |
| France, Germany, Netherlands | Minimal or no cost for approved drugs | National health insurance covers approved targeted therapies; formulary access varies |
| Australia (PBS) | Standard PBS co-payment (approx. AUD 30 per script for concession holders) | PBS listing required; targeted therapies increasingly listed after regulatory approval |
| USA (insured) | Co-pay after deductible; manufacturer co-pay cards common | Prior authorisation required; initial denials frequently overturned on appeal |
| USA (uninsured) | Manufacturer patient assistance programmes (often free drug) | Must be initiated before treatment starts; income criteria apply |
| India | Generic imatinib: very low; newer agents: variable | Strong generic industry; some newer targeted agents available at fraction of Western costs |
| Clinical trials (global) | Investigational drug provided at no cost | Standard of care components billed to insurance; applies to all countries |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About the Cost of Targeted Therapy for Your Case?
CancerFax helps patients understand insurance coverage, manufacturer assistance eligibility, and access pathways for targeted therapy in their specific country.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.